Multiple Sclerosis Market By Treatment Modality - Global Industry Analysis And Forecast To 2027
Published On : October 2018 Pages : 180 Category: Pharma & Healthcare Report Code : HC101468
Multiple Sclerosis Market By Treatment Modality (Oral Agents and Injectable Agents) - Global Industry Analysis And Forecast To 2027
Industry Outlook
The multi sclerosis (MS) is a conceivably impairing ailment of the spinal cord and brain (in all the central nervous system). In this disorder, the immune system assaults the defensive sheath (myelin) that protects the fibers of nerve and also causes the correspondence issues between the brain and other body parts. In the long run, the illness can make the nerves themselves decay or turn out to be forever harmed. The signs and the side effects of MS spread broadly and rely upon the measure of nerve harm and which of the nerves are been influenced. A few people with extreme MS may lose the capability to walk freely or by any means, while the others can encounter extensive stretches of reduction with no new indications. There's no remedy for MS, medications can help speed the recuperation from the assaults, change the course of the disorder and manage the side effects. Therefore, the Multiple Sclerosis Market is anticipated to expand and has tremendous scope during the forecast period. The global Multiple Sclerosis Market anticipated to flourish in the future by growing at a significantly higher CAGR.
Drivers & Restrains
The driving factors of the market are; the pharmaceutical organizations are focusing on the novel therapies to be commercialized that have minimum side effects & the economic pricing, more number of product launches by various companies, rising initiatives like the increasing funding for the research & development of the products, and others. The restraining factor of the market cab be thought to be the cost of the products as they are under developing stage.
Regional Insights
The North American region is leading the global Multiple Sclerosis Market pursued by European region owing to major methodologies adopted by the key players of the market.
Multiple Sclerosis Market, By Region
-
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and market share of the overall industry.
- Bayer
- Opexa
- Biogen Idec
- Active Biotech
- Novartis
- Synthetic Biologic
- EMD Serono
- Pfizer
- Sanofi
- Teva Pharmaceutical
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
o Multiple Sclerosis Market, By Treatment Modality, Estimates and Forecast, 2017-2027 ($Million)
o Oral Agents
o Injectable Agents
o Multiple Sclerosis Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Multiple Sclerosis Market , By Country
o U.S. Multiple Sclerosis Market
o Canada Multiple Sclerosis Market
o Mexico Multiple Sclerosis Market
o Europe
§ Europe Multiple Sclerosis Market , By Country
o Germany Multiple Sclerosis Market
o UK Multiple Sclerosis Market
o France Multiple Sclerosis Market
o Russia Multiple Sclerosis Market
o Italy Multiple Sclerosis Market
o Rest of Europe Multiple Sclerosis Market
o Asia-Pacific
§ Asia-Pacific Multiple Sclerosis Market , By Country
o China Multiple Sclerosis Market
o Japan Multiple Sclerosis Market
o South Korea Multiple Sclerosis Market
o India Multiple Sclerosis Market
o Southeast Asia Multiple Sclerosis Market
o Rest of Asia-Pacific Multiple Sclerosis Market
o South America
§ South America Multiple Sclerosis Market , By Country
o Brazil Multiple Sclerosis Market
o Argentina Multiple Sclerosis Market
o Columbia Multiple Sclerosis Market
o Rest of South America Multiple Sclerosis Market
o Middle East and Africa
§ Middle East and Africa Multiple Sclerosis Market , By Country
o Saudi Arabia Multiple Sclerosis Market
o UAE Multiple Sclerosis Market
o Egypt Multiple Sclerosis Market
o Nigeria Multiple Sclerosis Market
o South Africa Multiple Sclerosis Market
o Rest of MEA Multiple Sclerosis Market
Table of Contents
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. SWOT Analysis
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Multiple Sclerosis Market, By Treatment Modality
5.1. Introduction
5.2. Global Multiple Sclerosis Revenue and Market Share by Treatment Modality (2017-2027)
5.2.1. Global Multiple Sclerosis Revenue and Revenue Share by Treatment Modality (2017-2027)
5.3. Oral Agents
5.3.1. Global Oral Agents Revenue and Growth Rate (2017-2027)
5.4. Injectable Agents
5.4.1. Global Injectable Agents Revenue and Growth Rate (2017-2027)
6. Multiple Sclerosis Market, By Region
6.1. Introduction
6.2. Global Multiple Sclerosis Revenue and Market Share by Regions
6.2.1. Global Multiple Sclerosis Revenue by Regions (2017-2027)
6.3. North America Multiple Sclerosis by Countries
6.3.1. North America Multiple Sclerosis Revenue and Growth Rate (2017-2027)
6.3.2. North America Multiple Sclerosis Revenue (Million USD) by Countries (2017-2027)
6.3.3. United States
6.3.3.1. United States Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2027)
6.3.4. Canada
6.3.4.1. Canada Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2027)
6.3.5. Mexico
6.3.5.1. Mexico Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2027)
6.4. Europe Multiple Sclerosis by Countries
6.4.1. Europe Multiple Sclerosis Revenue and Growth Rate (2017-2027)
6.4.2. Europe Multiple Sclerosis Revenue (Million USD) by Countries (2017-2027)
6.4.3. Germany
6.4.3.1. Germany Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.4. France
6.4.4.1. France Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.5. UK
6.4.5.1. UK Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.6. Russia
6.4.6.1. Russia Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.7. Italy
6.4.7.1. Italy Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.8. Rest of Europe
6.4.8.1. Rest of Europe Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2027)
6.5. Asia-Pacific Multiple Sclerosis by Countries
6.5.1. Asia-Pacific Multiple Sclerosis Revenue and Growth Rate (2017-2027)
6.5.2. Asia-Pacific Multiple Sclerosis Revenue (Million USD) by Countries (2017-2027)
6.5.3. China
6.5.3.1. China Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.4. Japan
6.5.4.1. Japan Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.5. Korea
6.5.5.1. Korea Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.6. India
6.5.6.1. India Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.7. Southeast Asia
6.5.7.1. Southeast Asia Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.8. Rest of Asia-Pacific
6.5.8.1. Rest of Asia-Pacific Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2027)
6.6. South America Multiple Sclerosis by Countries
6.6.1. South America Multiple Sclerosis Revenue and Growth Rate (2017-2027)
6.6.2. South America Multiple Sclerosis Revenue (Million USD) by Countries (2017-2027)
6.6.3. Brazil
6.6.3.1. Brazil Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2027)
6.6.4. Argentina
6.6.4.1. Argentina Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2027)
6.6.5. Columbia
6.6.5.1. Columbia Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2027)
6.6.6. Rest of South America
6.6.6.1. Rest of South America Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2027)
6.7. Middle East and Africa Multiple Sclerosis by Countries
6.7.1. Middle East and Africa Multiple Sclerosis Revenue and Growth Rate (2017-2027)
6.7.2. Middle East and Africa Multiple Sclerosis Revenue (Million USD) by Countries (2017-2027)
6.7.3. Saudi Arabia
6.7.3.1. Saudi Arabia Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.4. United Arab Emirates
6.7.4.1. United Arab Emirates Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.5. Egypt
6.7.5.1. Egypt Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.6. Nigeria
6.7.6.1. Nigeria Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.7. South Africa
6.7.7.1. South Africa Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.8. Turkey
6.7.8.1. Turkey Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.9. Rest of Middle East and Africa
6.7.9.1. Rest of Middle East and Africa Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2027)
7. Company Profiles
7.1. Bayer
7.1.1. Business Overview
7.1.2. Service Portfolio
7.1.3. Strategic Developments
7.1.4. Revenue and Market Share
7.2. Opexa
7.2.1. Business Overview
7.2.2. Service Portfolio
7.2.3. Strategic Developments
7.2.4. Revenue and Market Share
7.3. Biogen Idec
7.3.1. Business Overview
7.3.2. Service Portfolio
7.3.3. Strategic Developments
7.3.4. Revenue and Market Share
7.4. Active Biotech
7.4.1. Business Overview
7.4.2. Service Portfolio
7.4.3. Strategic Developments
7.4.4. Revenue and Market Share
7.5. Novartis
7.5.1. Business Overview
7.5.2. Service Portfolio
7.5.3. Strategic Developments
7.5.4. Revenue and Market Share
7.6. Synthetic Biologic
7.6.1. Business Overview
7.6.2. Service Portfolio
7.6.3. Strategic Developments
7.6.4. Revenue and Market Share
7.7. EMD Serono
7.7.1. Business Overview
7.7.2. Service Portfolio
7.7.3. Strategic Developments
7.7.4. Revenue and Market Share
7.8. Pfizer
7.8.1. Business Overview
7.8.2. Service Portfolio
7.8.3. Strategic Developments
7.8.4. Revenue and Market Share
7.9. Sanofi
7.9.1. Business Overview
7.9.2. Service Portfolio
7.9.3. Strategic Developments
7.9.4. Revenue and Market Share
7.10. Teva Pharmaceutical
7.10.1. Business Overview
7.10.2. Service Portfolio
7.10.3. Strategic Developments
7.10.4. Revenue and Market Share
8. Global Multiple Sclerosis Market Competition, by Manufacturer
8.1. Global Multiple Sclerosis Revenue and Market Share by Manufacturer (2017-2017)
8.2. Global Multiple Sclerosis Price By Region (2017-2017)
8.3. Top 5 Multiple Sclerosis Manufacturer Market Share
8.4. Market Competition Trend
9. Multiple Sclerosis Market Forecast (2017-2027)
9.1. Global Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2027)
9.2. Multiple Sclerosis Market Forecast by Regions (2017-2027)
9.2.1. North America Multiple Sclerosis Market Forecast (2017-2027)
9.2.1.1. United States Multiple Sclerosis Market Forecast (2017-2027)
9.2.1.2. Canada Multiple Sclerosis Market Forecast (2017-2027)
9.2.1.3. Mexico Multiple Sclerosis Market Forecast (2017-2027)
9.2.2. Europe Multiple Sclerosis Market Forecast (2017-2027)
9.2.2.1. Germany Multiple Sclerosis Market Forecast (2017-2027)
9.2.2.2. France Multiple Sclerosis Market Forecast (2017-2027)
9.2.2.3. UK Multiple Sclerosis Market Forecast (2017-2027)
9.2.2.4. Russia Multiple Sclerosis Market Forecast (2017-2027)
9.2.2.5. Italy Multiple Sclerosis Market Forecast (2017-2027)
9.2.2.6. Rest of Europe Multiple Sclerosis Market Forecast (2017-2027)
9.2.3. Asia-Pacific Multiple Sclerosis Market Forecast (2017-2027)
9.2.3.1. China Multiple Sclerosis Market Forecast (2017-2027)
9.2.3.2. Japan Multiple Sclerosis Market Forecast (2017-2027)
9.2.3.3. Korea Multiple Sclerosis Market Forecast (2017-2027)
9.2.3.4. India Multiple Sclerosis Market Forecast (2017-2027)
9.2.3.5. Southeast Asia Multiple Sclerosis Market Forecast (2017-2027)
9.2.3.6. Rest of Asia-Pacific Multiple Sclerosis Market Forecast (2017-2027)
9.2.4. South America Multiple Sclerosis Market Forecast (2017-2027)
9.2.4.1. Brazil Multiple Sclerosis Market Forecast (2017-2027)
9.2.4.2. Argentina Multiple Sclerosis Market Forecast (2017-2027)
9.2.4.3. Columbia Multiple Sclerosis Market Forecast (2017-2027)
9.2.4.4. Rest of South America Multiple Sclerosis Market Forecast (2017-2027)
9.2.5. Middle East and Africa Multiple Sclerosis Market Forecast (2017-2027)
9.2.5.1. Saudi Arabia Multiple Sclerosis Market Forecast (2017-2027)
9.2.5.2. United Arab Emirates Multiple Sclerosis Market Forecast (2017-2027)
9.2.5.3. Egypt Multiple Sclerosis Market Forecast (2017-2027)
9.2.5.4. Nigeria Multiple Sclerosis Market Forecast (2017-2027)
9.2.5.5. South Africa Multiple Sclerosis Market Forecast (2017-2027)
9.2.5.6. Turkey Multiple Sclerosis Market Forecast (2017-2027)
9.2.5.7. Rest of Middle East and Africa Multiple Sclerosis Market Forecast (2017-2027)
9.3. Multiple Sclerosis Market Forecast by Treatment Modality (2017-2027)
9.3.1. Multiple Sclerosis Forecast by Treatment Modality (2017-2027)
9.3.2. Multiple Sclerosis Market Share Forecast by Treatment Modality (2017-2027)
List of Tables
List of Tables and Figures:
.
Figure United States Multiple Sclerosis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Multiple Sclerosis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Multiple Sclerosis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Multiple Sclerosis Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Multiple Sclerosis Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Multiple Sclerosis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Multiple Sclerosis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Multiple Sclerosis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Multiple Sclerosis Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Multiple Sclerosis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Multiple Sclerosis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Multiple Sclerosis Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Multiple Sclerosis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Multiple Sclerosis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Multiple Sclerosis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Multiple Sclerosis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Multiple Sclerosis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Multiple Sclerosis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Multiple Sclerosis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Multiple Sclerosis Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Multiple Sclerosis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Multiple Sclerosis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Multiple Sclerosis Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Multiple Sclerosis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Multiple Sclerosis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Multiple Sclerosis Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Multiple Sclerosis Revenue and Revenue Share by Treatment Modality (2017-2018)
Figure Global Oral Agents Revenue and Growth Rate (2017-2018)
Figure Global Injectable Agents Revenue and Growth Rate (2017-2018)
Table Global Multiple Sclerosis Revenue by Regions (2017-2018)
Figure North America Multiple Sclerosis Growth Rate (2017-2018)
Figure North America Multiple Sclerosis Revenue and Growth Rate (2017-2018)
Figure North America Multiple Sclerosis by Countries (2017-2018)
Figure North America Multiple Sclerosis Revenue (Million USD) by Countries (2017-2018)
Figure United States Multiple Sclerosis Growth Rate (2017-2018)
Figure United States Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Multiple Sclerosis Growth Rate (2017-2018)
Figure Canada Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Multiple Sclerosis Growth Rate (2017-2018)
Figure Mexico Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Multiple Sclerosis Growth Rate (2017-2018)
Figure Europe Multiple Sclerosis Revenue and Growth Rate (2017-2018)
Figure Europe Multiple Sclerosis by Countries (2017-2018)
Figure Europe Multiple Sclerosis Revenue (Million USD) by Countries (2017-2018)
Figure Germany Multiple Sclerosis Growth Rate (2017-2018)
Figure Germany Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Multiple Sclerosis Growth Rate (2017-2018)
Figure France Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Multiple Sclerosis Growth Rate (2017-2018)
Figure UK Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Multiple Sclerosis Growth Rate (2017-2018)
Figure Russia Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Multiple Sclerosis Growth Rate (2017-2018)
Figure Italy Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Multiple Sclerosis Growth Rate (2017-2018)
Figure Rest of Europe Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Multiple Sclerosis Growth Rate (2017-2018)
Figure Asia-Pacific Multiple Sclerosis Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Multiple Sclerosis by Countries (2017-2018)
Figure Asia-Pacific Multiple Sclerosis Revenue (Million USD) by Countries (2017-2018)
Figure China Multiple Sclerosis Growth Rate (2017-2018)
Figure China Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Multiple Sclerosis Growth Rate (2017-2018)
Figure Japan Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Multiple Sclerosis Growth Rate (2017-2018)
Figure Korea Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Multiple Sclerosis Growth Rate (2017-2018)
Figure India Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Multiple Sclerosis Growth Rate (2017-2018)
Figure Southeast Asia Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Multiple Sclerosis Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Multiple Sclerosis Growth Rate (2017-2018)
Figure South America Multiple Sclerosis Revenue and Growth Rate (2017-2018)
Figure South America Multiple Sclerosis by Countries (2017-2018)
Figure South America Multiple Sclerosis Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Multiple Sclerosis Growth Rate (2017-2018)
Figure Brazil Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Multiple Sclerosis Growth Rate (2017-2018)
Figure Argentina Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Multiple Sclerosis Growth Rate (2017-2018)
Figure Columbia Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Multiple Sclerosis Growth Rate (2017-2018)
Figure Rest of South America Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Multiple Sclerosis Growth Rate (2017-2018)
Figure Middle East and Africa Multiple Sclerosis Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Multiple Sclerosis by Countries (2017-2018)
Figure Middle East and Africa Multiple Sclerosis Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Multiple Sclerosis Growth Rate (2017-2018)
Figure Saudi Arabia Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Multiple Sclerosis Growth Rate (2017-2018)
Figure United Arab Emirates Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Multiple Sclerosis Growth Rate (2017-2018)
Figure Egypt Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Multiple Sclerosis Growth Rate (2017-2018)
Figure Nigeria Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Multiple Sclerosis Growth Rate (2017-2018)
Figure South Africa Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Multiple Sclerosis Growth Rate (2017-2018)
Figure Turkey Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Multiple Sclerosis Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2017-2018)
Table Bayer Multiple Sclerosis Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Opexa Multiple Sclerosis Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Biogen Idec Multiple Sclerosis Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Active Biotech Multiple Sclerosis Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Novartis Multiple Sclerosis Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Synthetic Biologic Multiple Sclerosis Price, Revenue, Gross Margin and Market Share (2017-2017)
Table EMD Serono Multiple Sclerosis Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Pfizer Multiple Sclerosis Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Sanofi Multiple Sclerosis Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Teva Pharmaceutical Multiple Sclerosis Price, Revenue, Gross Margin and Market Share (2017-2017)
Figure Global Multiple Sclerosis Market Share by Manufacturer
Figure Global Multiple Sclerosis Revenue and Market Share by Manufacturer
Table Global Multiple Sclerosis Price by Region (2017-2017)
Figure Top 5 Multiple Sclerosis Manufacturer (Revenue) Market Share
Figure Market Competition Trend
Figure Global Multiple Sclerosis Revenue (Millions USD) and Growth Rate (2018-2025)
Table Multiple Sclerosis Market Forecast by Regions (2018-2025)
Figure North America Multiple Sclerosis Market Forecast (2018-2025)
Figure United States Multiple Sclerosis Market Forecast (2018-2025)
Figure Canada Multiple Sclerosis Market Forecast (2018-2025)
Figure Mexico Multiple Sclerosis Market Forecast (2018-2025)
Figure Europe Multiple Sclerosis Market Forecast (2018-2025)
Figure Germany Multiple Sclerosis Market Forecast (2018-2025)
Figure France Multiple Sclerosis Market Forecast (2018-2025)
Figure UK Multiple Sclerosis Market Forecast (2018-2025)
Figure Russia Multiple Sclerosis Market Forecast (2018-2025)
Figure Italy Multiple Sclerosis Market Forecast (2018-2025)
Figure Rest of Europe Multiple Sclerosis Market Forecast (2018-2025)
Figure Asia-Pacific Multiple Sclerosis Market Forecast (2018-2025)
Figure China Multiple Sclerosis Market Forecast (2018-2025)
Figure Japan Multiple Sclerosis Market Forecast (2018-2025)
Figure Korea Multiple Sclerosis Market Forecast (2018-2025)
Figure India Multiple Sclerosis Market Forecast (2018-2025)
Figure Southeast Asia Multiple Sclerosis Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Multiple Sclerosis Market Forecast (2018-2025)
Figure South America Multiple Sclerosis Market Forecast (2018-2025)
Figure Brazil Multiple Sclerosis Market Forecast (2018-2025)
Figure Argentina Multiple Sclerosis Market Forecast (2018-2025)
Figure Columbia Multiple Sclerosis Market Forecast (2018-2025)
Figure Rest of South America Multiple Sclerosis Market Forecast (2018-2025)
Figure Middle East and Africa Multiple Sclerosis Market Forecast (2018-2025)
Figure Saudi Arabia Multiple Sclerosis Market Forecast (2018-2025)
Figure United Arab Emirates Multiple Sclerosis Market Forecast (2018-2025)
Figure Egypt Multiple Sclerosis Market Forecast (2018-2025)
Figure Nigeria Multiple Sclerosis Market Forecast (2018-2025)
Figure South Africa Multiple Sclerosis Market Forecast (2018-2025)
Figure Turkey Multiple Sclerosis Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Multiple Sclerosis Market Forecast (2018-2025)
Figure Global Multiple Sclerosis Forecast by Treatment Modality (2018-2025)
Figure Global Multiple Sclerosis Market Share Forecast by Treatment Modality (2018-2025)
Figure Global Multiple Sclerosis Forecast by Treatment Modality (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|